←ILMNIlluminaOur view: UnattractiveFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Illumina makes the machines that read DNA

Sequencers

machines that read DNA

Chemicals

used up on every run

Hospitals and labs

its buyers

Illumina sells machines that read DNA, and every run uses chemicals only it sells. Hospital, commercial and research labs buy them, with no customer above 10% of sales.

The company · 2 · What exactly does it sell?

Chemicals used per run are two thirds

Each $1 of sales, first half of 2026
67%14%11%9%
Chemicals per runServiceMachinesDNA chips

The machine is sold once; the chemicals are bought again on every run.

The company · 3 · How does it make money?

The machine once, the chemicals every run

74%of 2025 sales from chemicals
11%from machines
+14%hospital chemical sales

Each machine placed brings years of chemical sales, which only Illumina makes for it.

Is it a good business? · 4 · What gives it an edge?

Hospital tests are proven on its chemistry

83%

of volume on its newest machine

$50.0M

paid for a rival's patents

Each hospital test is proven on one machine's chemistry, so moving to a rival means repeating the accuracy runs and paperwork while patients wait.

Is it a good business? · 5 · What is the catch?

Roche has launched a sequencer

RocheAXELIOS 1, for research only so far
Elementpromises a much cheaper genome
MGItook the China market Illumina left

Listed rivals: ROP.SW

None is yet approved for hospital diagnosis, which is where Illumina's growth comes from.

Is it a good business? · 6 · What does its record show?

Flat sales for years, profit rebuilt by cuts

Sales, $B
4.5
4.6
4.5
4.4
4.3
4.5
Jan 2022Jan 2023Dec 2023Dec 2024Dec 2025last 12 mo
Sales$4.53B → $4.54Bsales, 2021 to the past year
Profit−19% → 21%operating profit per $1, since 2024
Growth+5.9%sales growth in the past year

Profit came back mostly as GRAIL was spun off and costs were cut, not from growth.

Is it a good business? · 7 · How much room is there to grow?

Cancer care is the big hospital use

2.11 millionAmericans diagnosed with cancer in 2026
34.5% to 62.9%of advanced patients sequenced

The share rose for every cancer type studied, but nobody publishes how many new diagnoses are advanced.

Is it a good business? · 8 · Who is in charge?

An Agilent veteran returned it to growth

September 2023Jacob Thaysen became chief executive
2024Ankur Dhingra took over finance
GRAILspun out

They spun out GRAIL and brought back growth, but 2025 still fell short.

The story right now · 9 · Why do hospitals read DNA?

Doctors read tumours' DNA to choose treatment

2.11 millionUS cancer diagnoses in 2026
+14%hospital chemical sales
−6%research chemicals

Doctors now read a tumour's DNA to choose the right drug. Hospitals buying more tests is offsetting weaker spending by research labs.

The story right now · 10 · How fast is Illumina really growing?

A purchase and currency flatter the growth

  1. Reported growth speeds upLooks like recovery.
  2. A purchase adds salesBought, not grown.
  3. Currency adds moreA weak dollar.
  4. A third comes offPer its own table.

The company's own table strips a third out of headline growth.

The story right now · 11 · What changed lately?

Profit target beaten, outlook raised

$1.129Bsales, up 4.2%
25.0%adjusted profit per $1, beat
14%hospital chemical growth
−6%research chemicals

Mixed quarter

The shares doubled in a year, helped by joining the S&P 500 on 21 September, when index funds had to buy.

The story right now · 12 · What is everyone arguing about?

Compounding again, or flattered?

Many investors think

Hospitals replaced lost sales and it compounds again

We think

The speed-up is flattered by a purchase and currency

We are wrong if hospital chemicals keep growing 15% or more through 2027.

The price and our view · 13 · What is a share worth?

The price sits above even our sunny case

$85.90what we think a share is worth
$85.90our value
Attractive
below $68.72
Neutral
Unattractive
above $103
$45.50gloomy: growth halves, less kept per $1
$85.90our estimate: experts' path, then slowing
$112sunny: growth beats the forecast by a quarter

Value per share in three futures. None is a prediction of the share price.

We estimate what a share is worth from the cash the business should earn over many years. Our rule: buy only when the price is at least a fifth below our estimate, as a cushion for being wrong.

The price and our view · 14 · How could we be wrong?

Roche's rival is the biggest threat

A rival from RocheBiggest

Research only, for now.

Research spending shrinksShowing now

Research chemicals fell.

The profit stepWatch

Not yet taken.

Hospital growthUnknown

Where it settles.

China stays closed, and cheaper genomes from rivals could pull prices down.

The price and our view · 15 · How will we know?

February brings the 2027 forecast

Hospital chemicals grow 15% or moreGood sign
Research sales stop fallingGood sign
Roche wins hospital approvalBad sign
FEB 20274

Fourth-quarter 2026 results and the 2027 forecast, 4 February. Companies report every three months; each report is a test of the story.

Our view also changes on price alone: if the shares fall to within a fifth of our estimate, we move to Neutral.

The price and our view · 16 · So, what do we think?

The DNA reading standard, priced as if recovery lasts

$85.90our value
Attractive
below $68.72
Neutral
Unattractive
above $103

UnattractiveHigh conviction

Illumina's machines read DNA, and every run uses chemicals only it sells. Sales grow again, led by hospitals, but a third of headline growth was a purchase and currency, and Roche has launched a rival.

↑ ↓ to move · C for contents